[go: up one dir, main page]

MX2012004338A - Formulaciones mejoradas. - Google Patents

Formulaciones mejoradas.

Info

Publication number
MX2012004338A
MX2012004338A MX2012004338A MX2012004338A MX2012004338A MX 2012004338 A MX2012004338 A MX 2012004338A MX 2012004338 A MX2012004338 A MX 2012004338A MX 2012004338 A MX2012004338 A MX 2012004338A MX 2012004338 A MX2012004338 A MX 2012004338A
Authority
MX
Mexico
Prior art keywords
metering valve
improved formulations
suspended
formulation
particles
Prior art date
Application number
MX2012004338A
Other languages
English (en)
Other versions
MX372991B (es
Inventor
Rudi Mueller-Walz
Lise-Marie Fueg
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012004338(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of MX2012004338A publication Critical patent/MX2012004338A/es
Publication of MX372991B publication Critical patent/MX372991B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En un inhalador de dosis medida, que comprende una lata y válvula dosificadora, que contiene una formulación en aerosol en suspensión que comprende partículas de fumarato de formoterol dihidratado y propionato de fluticasona suspendidas en un propelente de HFA, un método para reducir la deposición de partículas sobre la superficie de la lata y la válvula dosificadora, el método comprende el paso de agregar un agente humectante a la formulación.
MX2012004338A 2009-10-16 2010-10-15 Una formulacion en aerosol en suspension que comprende fumarato de fermoterol dihidratado y propionato de fluticasona suspendido en propelente de hpa y un agente humectante. MX372991B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918150.4A GB0918150D0 (en) 2009-10-16 2009-10-16 Improved formulations
PCT/EP2010/065569 WO2011045429A1 (en) 2009-10-16 2010-10-15 Improved formulations

Publications (2)

Publication Number Publication Date
MX2012004338A true MX2012004338A (es) 2012-08-01
MX372991B MX372991B (es) 2020-06-18

Family

ID=41462451

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004338A MX372991B (es) 2009-10-16 2010-10-15 Una formulacion en aerosol en suspension que comprende fumarato de fermoterol dihidratado y propionato de fluticasona suspendido en propelente de hpa y un agente humectante.

Country Status (25)

Country Link
US (2) US20120263766A1 (es)
EP (2) EP3811928A1 (es)
JP (2) JP5818801B2 (es)
CN (1) CN102573791B (es)
AU (1) AU2010305695B2 (es)
BR (1) BR112012008969B1 (es)
CA (1) CA2776845C (es)
CL (1) CL2012000948A1 (es)
CY (1) CY1123918T1 (es)
DK (1) DK2488157T3 (es)
ES (1) ES2859629T3 (es)
GB (1) GB0918150D0 (es)
HR (1) HRP20210379T1 (es)
HU (1) HUE054030T2 (es)
IL (2) IL219162A0 (es)
LT (1) LT2488157T (es)
MX (1) MX372991B (es)
NZ (1) NZ599900A (es)
PL (1) PL2488157T3 (es)
PT (1) PT2488157T (es)
RS (1) RS61430B1 (es)
SI (1) SI2488157T1 (es)
SM (1) SMT202100150T1 (es)
WO (1) WO2011045429A1 (es)
ZA (1) ZA201202595B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
JP6335798B2 (ja) * 2012-02-28 2018-05-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規噴射剤含有チオトロピウム製剤
MX2014011576A (es) 2012-04-11 2014-11-21 Cipla Ltd Composicion farmaceutica.
GB201321712D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
CN105963282B (zh) * 2016-05-04 2019-04-19 四川普锐特医药科技有限责任公司 一种医用定量吸入气雾剂
CN109789107B (zh) * 2016-09-29 2021-12-03 广东东阳光药业有限公司 药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
EP1908488A3 (en) 1995-04-14 2008-04-16 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
BR9604976A (pt) 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador de dose medida sistema inalador de dose medida e uso do mesmo
JPH101442A (ja) * 1996-06-12 1998-01-06 Taisho Pharmaceut Co Ltd 鼻炎用点鼻薬
ATE284677T1 (de) * 1997-03-20 2005-01-15 Schering Corp Herstellung von pulveragglomeraten
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
BR0015884A (pt) * 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
JP2004509031A (ja) 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド フルオロカーボンポリマーで２回以上コーティングした定量式吸入缶
HUP0302311A3 (en) * 2000-10-09 2006-07-28 3M Innovative Properties Co Medicinal aerosol formulations
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB0201400D0 (en) * 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
EP2319585A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, fluticasone and ipratropium or tiotropium
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0327727D0 (en) * 2003-11-28 2003-12-31 Quadrant Drug Delivery Ltd Viral microparticles
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations

Also Published As

Publication number Publication date
JP2016040286A (ja) 2016-03-24
CL2012000948A1 (es) 2012-12-14
GB0918150D0 (en) 2009-12-02
SI2488157T1 (sl) 2021-02-26
EP2488157A1 (en) 2012-08-22
US20170281529A1 (en) 2017-10-05
SMT202100150T1 (it) 2021-05-07
HRP20210379T1 (hr) 2021-04-16
LT2488157T (lt) 2021-02-10
PL2488157T3 (pl) 2021-06-28
AU2010305695B2 (en) 2014-07-10
BR112012008969B1 (pt) 2021-07-06
MX372991B (es) 2020-06-18
NZ599900A (en) 2014-11-28
IL269369A (en) 2019-11-28
ES2859629T3 (es) 2021-10-04
US20120263766A1 (en) 2012-10-18
HUE054030T2 (hu) 2021-08-30
BR112012008969A2 (pt) 2020-06-23
EP2488157B1 (en) 2020-12-30
WO2011045429A1 (en) 2011-04-21
US20180296468A2 (en) 2018-10-18
CA2776845A1 (en) 2011-04-21
CY1123918T1 (el) 2022-05-27
RS61430B1 (sr) 2021-03-31
PT2488157T (pt) 2021-02-05
ZA201202595B (en) 2023-07-26
CN102573791A (zh) 2012-07-11
DK2488157T3 (da) 2021-01-25
CA2776845C (en) 2018-04-24
JP2013507429A (ja) 2013-03-04
CN102573791B (zh) 2017-09-22
AU2010305695A1 (en) 2012-05-03
IL219162A0 (en) 2012-06-28
JP5818801B2 (ja) 2015-11-18
EP3811928A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
MX2012004338A (es) Formulaciones mejoradas.
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
MX393243B (es) Composición farmacéutica que comprende la combinación de albuterol y budesónida, adaptada para el suministro respiratorio mediante un inhalador de dosis medida y el uso de las mismas para el tratamiento de trastornos pulmonares.
CL2022002235A1 (es) Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada
PE20140101A1 (es) Formulacion para inhalacion que comprende aclidinio
PH12013502270A1 (en) Compositions, methods & systems for respiratory delivery of two or more active agents
TW201129359A (en) Pharmaceutical composition for the treatment of COPD
HK1221653A1 (zh) 用於呼吸递送三种或更多种活性剂的组合物、方法和系统
MX2014004279A (es) Composiciones que comprenden sulfato de salbutamol.
GB201118188D0 (en) Manufacture of medicinal aerosol canisters
AR083208A1 (es) Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion
MX2014004364A (es) Composiciones que comprenden sulfato de salbutamol.
MX2020003436A (es) Inhalador de polvo seco y metodo de uso.
MX2015014513A (es) Composicion que comprende sulfato de salbutamol.
CL2022002008A1 (es) Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
CL2014003211A1 (es) Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende
WO2013104892A8 (en) Application of high dose compounds via inhalation
CL2012000947A1 (es) Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
AR067459A1 (es) Inhalador
AR089101A1 (es) Formulacion nasal
BR102012008322B8 (pt) formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa
CR9941A (es) Formacion farmaceutica de absorcion oral y su metodo de administracion

Legal Events

Date Code Title Description
GD Licence granted
GD Licence granted
FG Grant or registration